Many medical manufacturers perceive the value of incorporating patients’ experiences and outcomes in R&D processes as a way to align research efforts with patients’ needs. To ensure that appropriate frameworks and metrics are available for such patient-focused R&D, manufacturers have developed internally facing and externally facing metrics to quantify the impact of patient engagement (PE) and have devised tools to calculate appropriate renumeration for patients’ R&D participation. Among pharma researchers, collaborative industries, and investors, interest is emerging as to how manufacturers’ ESG goals can align with PE, and how ESG metrics could be used to quantify the impact of investment dollars and PE-related metrics. This discussion will explore the perspectives of biotech and pharma researchers, their research collaborators, and investors on the perceived value of PE efforts, approaches to quantify the value of such efforts, and the utility of emerging R&D frameworks.

Moderator

Cyndi Grossman

Head of Realworld Research Networks, Biogen

Speakers

Nicholas Brooke

Executive Director, Patient Focused Medicines Development, The Synergist

Patricia Furlong

President and CEO, Parent Project Muscular Dystrophy

Joep Muijrers

General Partner, Public Investments, Venture and Growth, Gilde Healthcare

Neena Patil

Executive Vice President and Chief Legal Officer, Jazz Pharmaceuticals

Eric Racine

Vice President and US Country Head, Public Affairs and Patient Advocacy, Sanofi